Clinical Trials Browser

INDUSTRY × Neuroblastoma × 1 year × Clear all

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT06395103 2026-03-11

MK-9999-01A

Phase 1/2 Recruiting

90 enrolled

CNSLymphoidSarcoma

Burkitt Lymphoma, Neuroblastoma, Sarcoma, Ewing, Lymphoma, Large B-Cell, Diffuse

NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Phase 2 Completed

20 enrolled

CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Phase 1/2 Completed

47 enrolled 36 charts

CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT03363373 2026-02-19

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Phase 2 Recruiting

122 enrolled 2 FDA

CNS

Neuroblastoma

NCT03975829 2026-02-13

Pediatric Long-Term Follow-up and Rollover Study

Phase 4 Active not recruiting

163 enrolled

CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT05642455 2026-02-09

SPEARHEAD-3 Pediatric Study

Phase 1/2 Recruiting

20 enrolled

CNSSarcoma

Neuroblastoma, Osteosarcoma, Sarcoma, Synovial, Neurofibrosarcoma

NCT04544995 2026-01-21

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

Phase 1 Terminated

47 enrolled 43 charts

CNSSarcoma

Neoplasms, Neuroblastoma, Osteosarcoma

NCT02650401 2025-12-24

STARTRK-NG

Phase 1/2 Active not recruiting

69 enrolled 1 FDA

CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT05429502 2025-10-10

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Phase 1 Terminated

12 enrolled

CNSSarcoma

Glioma, Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma

NCT04337177 2025-09-23

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

Phase 1 Recruiting

20 enrolled

CNSGastrointestinalSarcoma

Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma

NCT04023331 2025-09-16

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Phase 1/2 Terminated

21 enrolled

CNS

Neuroblastoma

NCT04610736 2025-07-31

TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide

Phase 1 Completed

49 enrolled

CNS

Neoplasms, Neuroblastoma

NCT04106219 2025-07-23

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Phase 1 Active not recruiting

71 enrolled

CNS

Epilepsy, Neuroblastoma

NCT06872489 2025-07-23

Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors

Available

CNSGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Neuroblastoma, Pancreatic Neoplasms, Recurrence

NCT04239092 2025-07-17

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Phase 1 Terminated

40 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Meningioma, Neoplasms, Neuroblastoma

NCT06674265 2025-04-09

Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma

Phase 1 Recruiting

10 enrolled

CNS

Neuroblastoma, Recurrence

NCT04724369 2025-03-26

Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

Phase 3 Completed

43 enrolled

CNS

Neuroblastoma

Clinical Trials

CLOVER-2

MK-9999-01A

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Pediatric Long-Term Follow-up and Rollover Study

SPEARHEAD-3 Pediatric Study

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

STARTRK-NG

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma

Open-Label Study of 18F-mFBG for Imaging Neuroblastoma